Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

BI Xin ¹ , GUO Juntang ² ,  ZHANG Zhimin ¹

1. Department of Chest Surgery, The Third Medical Center of The General Hospital of The People’s Liberation Army, Beijing 100039, P. R. China;
2. Department of Chest Surgery, The First Medical Center of The General Hospital of the People’s Liberation Army, Beijing 100853, P. R. China;

Corresponding author：

ZHANG Zhimin, Email: 774022337@qq.com

Keywords：

Long chain non-coding RNA nicotinamide nucleotide hydrogenase antisense RNA1; motor neuron and pancreas homeobox protein 1 antisense RNA 1; lung cancer

DOI：

10.7507/1671-6205.202404053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression and clinical value of long chain non-coding RNA nicotinamide nucleotide hydrogenase antisense RNA1 (LncRNA NNT-AS1), motor neuron and pancreas homeobox protein 1 antisense RNA1 (MNX1-AS1) in lung cancer patients. Methods This study selected 128 patients diagnosed with lung cancer admitted to The Third Medical Center of the General Hospital of the People’s Liberation Army from April 2020 to April 2021 as a cancer group. During the same period, 128 patients with benign pulmonary nodules were regarded as a benign group, and 128 healthy individuals who underwent physical examination were selected as a control group. Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the levels of LncRNA NNT-AS1 and MNX1-AS1 in serum. A three-year follow-up was conducted on all lung cancer patients, with 52 patients in the death group and 76 patients in the survival group. Receiver operator characteristic (ROC) curve was applied to analyze the diagnostic value of serum LncRNA NNT-AS1 and MNX1-AS1 for the occurrence of lung cancer and their predictive value for prognosis. Results Compared with the control group, the serum levels of LncRNA NNT-AS1 and MNX1-AS1 were obviously increased in the benign group and the cancer group (P<0.05). Compared with the benign group, the levels of LncRNA NNT-AS1 and MNX1-AS1 in serum of the cancer patients were obviously increased (P<0.05). The area under ROC curve (AUC) of serum LncRNA NNT-AS1 combined with MNX1-AS1 for the diagnosis of lung cancer was higher than that of LncRNA NNT-AS1 and MNX1-AS1 alone (Z_{LncRNA NNT-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.496, P=0.013; Z_{MNX1-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.831, P=0.007). The levels of LncRNA NNT-AS1 and MNX1-AS1 were related to tumor differentiation, clinical stage, and lymph node metastasis (P<0.05). Compared with the survival group, the serum levels of LncRNA NNT-AS1 and MNX1-AS1 in the death group were obviously increased (P<0.05). The AUC of combined prediction for lung cancer prognosis by serum LncRNA NNT-AS1 and MNX1-AS1 was higher than that predicted by LncRNA NNT-AS1 and MNX1-AS1 alone (Z_{LncRNA NNT-AS1~LncRNA NNT-AS1+MNX1-AS1}=2.539, P=0.011; Z_{MNX1-AS1~LncRNA NNT-AS1+MNX1-AS1}=3.377, P=0.001). Conclusion LncRNA NNT-AS1 and MNX1-AS1 are highly expressed in serum of lung cancer patients, and both have certain value in diagnosis and prognosis evaluation of lung cancer.

Citation： BI Xin, GUO Juntang, ZHANG Zhimin. Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(2): 86-91. doi: 10.7507/1671-6205.202404053 Copy

1.	胡博文, 杜玲玉, 杨勇. CTCs作为NSCLC诊断预后指标及在PD-1/PD-L1免疫治疗中的研究回顾. 中文科技期刊数据库(引文版)医药卫生, 2022, 6(2): 10-15.
2.	饶德新, 潘丽红, 刘恒, 等. 血清miR-134-5p和趋化因子20对非小细胞肺癌患者肺癌根治术后复发转移的预测价值. 中华实用诊断与治疗杂志, 2022, 36(2): 130-135.
3.	赵齐林, 王楠, 李亚霁, 等. Lnc-TMEM132D-AS1高表达明显降低非小细胞肺癌对奥希替尼的敏感性. 南方医科大学学报, 2023, 43(2): 242-250.
4.	马宇光, 昝瑛, 王梦, 等. LncRNA NNT-AS1和miR-424在子宫内膜癌组织中的表达及其临床意义. 国际检验医学杂志, 2021, 42(11): 1376-1381.
5.	Yang R, Wang L, Han M. MNX1-AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma. J Cell Biochem, 2019, 120(5): 7222-7228.
6.	中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版). 中华肿瘤杂志, 2018, 40(12): 935-964.
7.	罗巧, 石宏, 王绍波. α7-烟碱乙酰胆碱受体在肺癌发生, 发展及治疗中的作用. 昆明医科大学学报, 2022, 43(2): 145-149.
8.	赵曼, 祝德, 张洪洋. 巴中市非小细胞肺癌患者EGFR基因突变及环境暴露因素分析. 公共卫生与预防医学, 2023, 34(4): 128-131.
9.	闫星, 刘山梅, 刘长宏. 不同体液标本活检在肺癌微小残留疾病监测中的应用最新进展. 中国全科医学, 2023, 26(3): 280-286.
10.	赵娜, 丁宁, 朱蓉. 不同肿瘤分期肺癌合并下肢静脉血栓患者的炎症因子, 凝血及纤溶指标表达水平的差异及其与疾病的相关性分析. 临床和实验医学杂志, 2023, 22(5): 457-461.
11.	贾刚刚, 李斌, 卢利霞, 等. 长链非编码RNA-NEF在肝癌, 胃癌, 食管癌发生发展中的作用. 中国医药导报, 2023, 20(12): 52-55.
12.	刘尚, 郭莉媛. 长链非编码RNA AFAP1-AS1在实体肿瘤中的作用与分子机制. 现代肿瘤医学, 2020, 28(8): 1390-1394.
13.	郎海雷, 曹雷涛, 贵英斌, 等. LncRNANNT-AS1通过调控miR-582-5p/NCKAP1轴激活Hippo-YAP/TAZ信号通路促进膀胱癌细胞增殖, 迁移, 侵袭和干细胞干性影响. 现代检验医学杂志, 2023, 38(4): 27-34.
14.	Hua F , Liu S , Zhu L , et al. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer. Biomed Pharmacother, 2017, 92: 1128-1134.
15.	刘高峰, 张勇, 张小贞, 等. LncRNA MNX-AS1在非小细胞肺癌组织中的表达及临床意义. 河北医学, 2021, 27(3): 486-490.
16.	叶晖. LncRNA NNT--AS1过表达与骨肉瘤进展及不良预后的相关性研究. 广州: 南方医科大学, 2023.
17.	Yin H, Hu J, Ye Z, et al. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer. Mol Med Rep, 2021, 24(2): 585-597.
18.	Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci, 2018, 22(4): 4879-4887.
19.	Shuai Y, Ma Z, Liu W, et al. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer, 2020, 19(1): 6-18.
20.	Liu G, Zhang Y, Zhang X, et al. LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis. Am J Transl Res, 2022, 14(7): 4977-4989.
21.	Shen Y, Lv M, Fang Y, et al. LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis. J Ovarian Res, 2021, 14(1): 161-179.
22.	Braga EA, Fridman MV, Burdennyy AM, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci, 2023, 24(17): 13617-13625.

1. 胡博文, 杜玲玉, 杨勇. CTCs作为NSCLC诊断预后指标及在PD-1/PD-L1免疫治疗中的研究回顾. 中文科技期刊数据库(引文版)医药卫生, 2022, 6(2): 10-15.
2. 饶德新, 潘丽红, 刘恒, 等. 血清miR-134-5p和趋化因子20对非小细胞肺癌患者肺癌根治术后复发转移的预测价值. 中华实用诊断与治疗杂志, 2022, 36(2): 130-135.
3. 赵齐林, 王楠, 李亚霁, 等. Lnc-TMEM132D-AS1高表达明显降低非小细胞肺癌对奥希替尼的敏感性. 南方医科大学学报, 2023, 43(2): 242-250.
4. 马宇光, 昝瑛, 王梦, 等. LncRNA NNT-AS1和miR-424在子宫内膜癌组织中的表达及其临床意义. 国际检验医学杂志, 2021, 42(11): 1376-1381.
5. Yang R, Wang L, Han M. MNX1-AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma. J Cell Biochem, 2019, 120(5): 7222-7228.
6. 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版). 中华肿瘤杂志, 2018, 40(12): 935-964.
7. 罗巧, 石宏, 王绍波. α7-烟碱乙酰胆碱受体在肺癌发生, 发展及治疗中的作用. 昆明医科大学学报, 2022, 43(2): 145-149.
8. 赵曼, 祝德, 张洪洋. 巴中市非小细胞肺癌患者EGFR基因突变及环境暴露因素分析. 公共卫生与预防医学, 2023, 34(4): 128-131.
9. 闫星, 刘山梅, 刘长宏. 不同体液标本活检在肺癌微小残留疾病监测中的应用最新进展. 中国全科医学, 2023, 26(3): 280-286.
10. 赵娜, 丁宁, 朱蓉. 不同肿瘤分期肺癌合并下肢静脉血栓患者的炎症因子, 凝血及纤溶指标表达水平的差异及其与疾病的相关性分析. 临床和实验医学杂志, 2023, 22(5): 457-461.
11. 贾刚刚, 李斌, 卢利霞, 等. 长链非编码RNA-NEF在肝癌, 胃癌, 食管癌发生发展中的作用. 中国医药导报, 2023, 20(12): 52-55.
12. 刘尚, 郭莉媛. 长链非编码RNA AFAP1-AS1在实体肿瘤中的作用与分子机制. 现代肿瘤医学, 2020, 28(8): 1390-1394.
13. 郎海雷, 曹雷涛, 贵英斌, 等. LncRNANNT-AS1通过调控miR-582-5p/NCKAP1轴激活Hippo-YAP/TAZ信号通路促进膀胱癌细胞增殖, 迁移, 侵袭和干细胞干性影响. 现代检验医学杂志, 2023, 38(4): 27-34.
14. Hua F , Liu S , Zhu L , et al. Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer. Biomed Pharmacother, 2017, 92: 1128-1134.
15. 刘高峰, 张勇, 张小贞, 等. LncRNA MNX-AS1在非小细胞肺癌组织中的表达及临床意义. 河北医学, 2021, 27(3): 486-490.
16. 叶晖. LncRNA NNT--AS1过表达与骨肉瘤进展及不良预后的相关性研究. 广州: 南方医科大学, 2023.
17. Yin H, Hu J, Ye Z, et al. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer. Mol Med Rep, 2021, 24(2): 585-597.
18. Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci, 2018, 22(4): 4879-4887.
19. Shuai Y, Ma Z, Liu W, et al. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer, 2020, 19(1): 6-18.
20. Liu G, Zhang Y, Zhang X, et al. LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis. Am J Transl Res, 2022, 14(7): 4977-4989.
21. Shen Y, Lv M, Fang Y, et al. LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis. J Ovarian Res, 2021, 14(1): 161-179.
22. Braga EA, Fridman MV, Burdennyy AM, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci, 2023, 24(17): 13617-13625.

Chinese Journal of Respiratory and Critical Care Medicine

Expression and clinical value of LncRNA NNT-AS1 and MNX1-AS1 in lung cancer patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content